As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...
In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form ...
Base editing corrected a mutation that causes macular degeneration, highlighting the potential of gene therapy to treat ...
Scientists developed a promising gene replacement therapy for Dravet syndrome in mice. The therapy alleviated symptoms ...
LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approv ...
A new study in the journal Human Gene Therapy indicates that DNA impurities derived from plasmid and host cell DNA are ...
In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form ...
With a storied history in vaccine development, India's Bharat Biotech is shaking things up and answering the call of advanced ...
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech ...
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category Oxford, UK – 21 March 2025: OXB (LSE: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback